360A iodide
(Synonyms: 360A碘化物,360 A iodide) 目录号 : GC10115360A iodide 是 G-quadruplex 的选择性稳定剂,也抑制端粒酶活性,在 TRAP-G4 试验中对端粒酶的 IC50 为 300 nM。
Cas No.:737763-37-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
The cell proliferation reagent WST-1 assay is performed. In brief, cells are seeded at various densities, depending on cell type (0.25-4 × 103 cells/well in 100 μL complete medium), in 96-well culture plates and treated with various concentrations (0.1-20 μM) of 360A or the corresponding concentrations of DMSO (control wells) for 3 or 7 days at 37°C in an atmosphere containing 5% CO2. For 7-day assays, the medium is changed on day 3. Experiments are performed in triplicate[1]. |
References: [1]. Pennarun G, et al. Apoptosis related to telomere instability and cell cycle alterations in human glioma cells treated by new highly selective G-quadruplex ligands. Oncogene. 2005 Apr 21;24(18):2917-28. |
360A is a 2,6-pyridine-dicarboxamide derivative displaying strong affinity and selectivity for G-quadruplex structures and selective telomerase inhibition in vitro assays. 360A is a G-quadruplex ligand, which can influence the consequence of G-quadruplex formation and/or stabilization. in vitro: We found a S-phase accumulation in ATM-proficient, but not in ATM-deficient EBV-lymphocytes treated with 360A before induction of cell death. However, ATM status did not modify cell cycle distribution in 360A-treated SV40-fibroblasts and HeLa cells compared to DMSO treated controls [1]. DNA-PKcs-dependent NHEJ was responsible for sister telomere fusions as a direct consequence of G-quadruplex formation and/or stabilization induced by 360A on parental telomere G strands. NHEJ and HR activation at telomeres altered mitotic progression in treated cells [2]. This compound was shown to display a potent affinity and selectivity for telomeric G-quadruplex DNA over duplex DNA and to induce delayed growth inhibition in HT1080 tumor cell line [3]
Cas No. | 737763-37-0 | SDF | |
别名 | 360A碘化物,360 A iodide | ||
化学名 | (3Z,3'Z)-3,3'-((pyridine-2,6-dicarbonyl)bis(azanylylidene))bis(1-methyl-2,3-dihydroquinolin-1-ium-2-ide) dihydroiodide | ||
Canonical SMILES | CN1=C2C=CC=CC2=C/C(C=1)=N/C(C3=NC(C(/N=C4C=C5C=CC=CC5=N(C)=C/4)=O)=CC=C3)=O.I.I | ||
分子式 | C27H23I2N5O2 | 分子量 | 703.31 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.4218 mL | 7.1092 mL | 14.2185 mL |
5 mM | 0.2844 mL | 1.4218 mL | 2.8437 mL |
10 mM | 0.1422 mL | 0.7109 mL | 1.4218 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。